Gene doping

Gene doping is the use of gene transfer, gene editing or gene regulation to improve athletic performance rather than to treat disease. It has been prohibited in competitive sport since the early 2000s, before any technique for doing it existed, and it remains prohibited today. No case has been publicly confirmed in an elite athlete. The gap between a prohibition written in anticipation and an offence nobody has proved is the defining feature of the subject.

§The targets

The candidate genes come from exercise physiology and from muscle-disease research, where the same constructs are studied as therapies.

Erythropoietin. EPO drives red-cell production and therefore oxygen delivery. Recombinant EPO is the classic endurance drug; a gene-transfer version would in principle produce it endogenously and continuously. That constancy is also the main hazard, since expression from a viral vector cannot easily be turned down.

Myostatin and its antagonists. Blocking myostatin increases muscle mass, an effect established in cattle, dogs and mice, and pursued clinically for muscle-wasting disease. Follistatin constructs delivered by adeno-associated virus are the most plausible muscle-directed doping agent, for the simple reason that they have been administered to humans outside clinical trials. The biology and its disappointments are set out in Myostatin inhibition.

IGF-1. Local delivery of insulin-like growth factor 1 by viral vector increased muscle mass and preserved function in aging mice, a result from the late 1990s that gave gene doping its earliest popular image.¹

Metabolic switches. Transgenic mice overexpressing the nuclear receptor PPARδ in muscle showed a shift toward oxidative fibres and greatly increased running endurance, and pharmacological agonists reproduced part of the effect.² Follow-up work on AMPK and PPARδ agonists framed these compounds as exercise mimetics, and the small molecules involved were added to the prohibited list well before any gene-transfer version was attempted.³

Angiogenic and hypoxia pathways. VEGF and stabilised HIF constructs would increase capillary density or mimic altitude adaptation. These remain conjectural in the doping context.

§Why it is prohibited

The World Anti-Doping Agency lists gene and cell doping as method class M3. The wording is deliberately broad, covering the use of nucleic acid polymers or analogues that alter genome sequences or gene expression by any mechanism, and the use of normal or genetically modified cells.⁴ The 2018 revision of the list extended the class explicitly to gene-editing agents, which brought CRISPR–Cas9 and its derivatives inside the rule, so an epigenetic intervention that raised expression of a native gene without introducing foreign DNA is prohibited even though it would leave no transgene to find.

Prohibition rests on the same rationale set out in Enhancement in sport: health risk, the integrity of competition, and the coercion of athletes who would otherwise decline. The rule is unusual in one respect. Nearly every other class on the list names substances that exist and are available; M3 anticipates a method, and the anticipated version of it is closer to Gene therapy for aging in its ambitions than to a steroid. Gene transfer sharpens the first of these, because a viral vector cannot be withdrawn. An athlete who over-responds to an EPO construct has no route back short of therapeutic intervention against their own transgene.

§Detection

Detection strategies fall into three families.

• Direct transgene detection. A therapeutic construct is usually built from complementary DNA, which lacks the introns present in the genomic copy of the same gene. A polymerase chain reaction assay spanning an exon-exon junction distinguishes the two, and anti-doping laboratories have developed and validated such assays for the leading candidates. The method works well on blood, and less well if the vector was injected into a single muscle and never entered circulation in quantity.
• Vector detection. Residual viral capsid sequences and anti-capsid antibodies persist after administration, which turns pre-existing vector immunity into a potential forensic signal.
• Indirect signatures. The Athlete Biological Passport tracks haematological and steroidal variables over time and flags deviations from an athlete's own baseline, regardless of cause. Transcriptomic and proteomic signatures of altered gene expression have been proposed as a complementary approach, though establishing the specificity needed for a sanction is difficult.

Absence of evidence

No publicly confirmed positive test for gene doping in an elite athlete exists as of 2026. Whether that reflects absence of the practice or the difficulty of catching it is unresolved; anti-doping scientists generally argue both contribute.

§Documented and alleged cases

1. 1998
   Muscle gene transfer in mice
   Viral delivery of IGF-1 to mouse muscle increases mass and preserves function with age, and is immediately discussed as a doping risk.
2. 2002–2003
   Anti-doping response
   WADA convenes scientific meetings on gene transfer and adds gene doping to the Prohibited List before any means of doing it is available.
3. 2004
   Endurance transgenics
   Transgenic mice overexpressing PPARδ show large increases in running endurance, producing the 'marathon mouse' framing.
4. 2006
   Repoxygen
   In the trial of German athletics coach Thomas Springstein, correspondence emerges in which he seeks Repoxygen, an experimental EPO gene-therapy construct. No evidence of administration to an athlete is established.
5. 2015–2025
   Unregulated self-administration
   Follistatin gene-transfer products are offered outside clinical trials by companies operating in permissive jurisdictions and taken by self-experimenters, demonstrating that access does not depend on approval.

The Repoxygen episode remains the closest thing to a documented attempt, and even there the evidence is of intent rather than of use. The more consequential development has been outside sport altogether: as described in Biohacking and grinders, gene-transfer products have been sold directly to individuals by companies based in jurisdictions with light regulation, which establishes that an athlete determined to try this would not need a laboratory of their own.

§Risks

The safety profile is inherited from Somatic gene therapy, where it has been characterised in patients who had a disease justifying the risk. Immune responses to the vector and to the transgene product are the dominant hazard; high-dose systemic AAV has caused serious liver injury and deaths in clinical trials for muscle disease. Gene transfer of erythropoietin in macaques produced, in several animals, an immune response that cross-reacted with native erythropoietin and caused severe anaemia, precisely inverting the intended effect.⁵ Insertional mutagenesis is a smaller but real concern with integrating vectors, the genome-level damage catalogued in Off-target effects in genome editing applies to any editing-based version, and uncontrolled expression is a structural problem rather than a dosing error.

None of these risks are acceptable in a healthy adult seeking a competitive margin, which is the standard bioethical objection and also the practical reason clinicians decline to provide it. The comparison that anti-doping physicians draw is with training itself, which produces adaptations in the same pathways with a known safety profile and no vector.

§The Enhanced Games and the open-doping argument

The Enhanced Games, announced in 2023 and backed by private investors, proposes competition without anti-doping rules, on the argument that supervised enhancement is safer than the clandestine kind and that records suppressed by prohibition would otherwise be achievable. In 2025 the organisers publicised a swim faster than a long-standing world-record mark, achieved outside sanctioned conditions; world federations rejected the comparison and several moved to bar participants from their events.

The venture's stated emphasis has been pharmacological, and its position on gene transfer has been less clearly articulated than its position on drugs. It nonetheless supplies the sharpest version of the argument in Enhancement arms race: if a parallel competition removes the rule, the collective-action structure that makes prohibition stable in the first place weakens, and the question of who is protected by the ban becomes concrete. Critics reply that medical supervision does not make an unapproved AAV construct safe, and that the athletes bearing the risk are not the people capitalising the event. The venture is also the clearest current test of whether Human enhancement can be normalised by staging it in public rather than by arguing for it.

§Outlook

Two developments would change the picture. The first is the maturation of delivery: as non-viral delivery improves and transient expression becomes routine, a doping agent that clears the body would be far harder to detect than an integrated or episomal transgene that persists. The second is the spread of expression-modulating tools that add no foreign sequence at all, for which the forensic question is not whether a construct is present but whether an athlete's own regulatory state is natural.

Anti-doping science is preparing for both, mainly through longitudinal profiling that looks for anomalous stability or change in an athlete's own biology rather than for a foreign molecule. Whether a sanction can ever be sustained on that basis, against the evidentiary standard arbitration panels apply, has not been tested.

§See also

• Enhancement in sport
• Myostatin inhibition
• Somatic gene therapy
• AAV vectors
• Human enhancement
• Biohacking and grinders
• Enhancement arms race
• Exercise as a geroprotector

§References